AR057626A1 - Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor - Google Patents
Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtorInfo
- Publication number
- AR057626A1 AR057626A1 ARP060105124A ARP060105124A AR057626A1 AR 057626 A1 AR057626 A1 AR 057626A1 AR P060105124 A ARP060105124 A AR P060105124A AR P060105124 A ARP060105124 A AR P060105124A AR 057626 A1 AR057626 A1 AR 057626A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- group
- aryl group
- heteroaryl
- alkyl group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000006413 ring segment Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) donde: uno o dos de X5, X6 y X8 es N, y los demás son CH; R7 se selecciona entre halo, ORO1, SRS1, NRN1RN2, NRN7aC(=O)RC1, NRN17bSO2RS2a, un grupo C5-20 heteroarilo optativamente sustituido, o un grupo C5-20 arilo optativamente sustituido, donde RO1 y RS1 se seleccionan entre H, un grupo C5-20 arilo optativamente sustituido, un grupo C5-20 heteroarilo optativamente sustituido, o un grupo C1-7alquilo optativamente sustituido; RN1 y RN2 se seleccionan independientemente entre H, un grupo C1-7 alquilo optativamente sustituido, un grupo C5-20 heteroarilo optativamente sustituido, un grupo C5-20 arilo optativamente sustituido o RN1 y RN2 junto con el N al cual están unidos forman un anillo heterocíclico que contiene entre 3 y 8 átomos en el anillo; RC1 se selecciona entre H, un grupo C5-20 arilo optativamente sustituido, un grupo C5-20 heteroarilo optativamente sustituido, un grupo C1-7 alquilo optativamente sustituido o NRN8RN9, donde RN8 y RN9 se seleccionan independientemente entre H, un grupo C1-7 alquilo optativamente sustituido, un grupo C5-20 heteroarilo optativamente sustituido, un grupo C5-20 arilo optativamente sustituido o RN8 y RN9 junto con el N al cual están unidos forman un anillo heterocíclico que contiene entre 3 y 8 átomos en el anillo; RS2a se selecciona entre H, un grupo C5-20 arilo optativamente sustituido, un grupo C5-20 heteroarilo optativamente sustituido, o un grupo C1-7 alquilo optativamente sustituido; RN7a y RN7b se seleccionan entre H y un grupo C1-4 alquilo; RN3 y RN4, junto con el N al cual están unidos, forman un anillo heterocíclico que contiene entre 3 y 8 átomos en el anillo; R2 se selecciona entre H, halo, ORO2, SRS2b, NRN5RN6, un grupo C5-20 heteroarilo optativamente sustituido, y un grupo C5-20 arilo optativamente sustituido; donde RO2 y RS2b se seleccionan entre H, un grupo C5-20 arilo optativamente sustituido, un grupo C5-20 heteroarilo optativamente sustituido, o un grupo C1-7 alquilo optativamente sustituido; RN5 y RN6 se seleccionan independientemente entre H, un grupo C1-7 alquilo optativamente sustituido, un grupo C5-20 heteroarilo optativamente sustituido, y un grupo C5-20 arilo optativamente sustituido, o RN5 y RN6 junto con el N al cual están unidos forman un anillo heterocíclico que contiene entre 3 y 8 átomos en el anillo; o una sal aceptable para uso farmacéutico de los mismos, con la salvedad de que cuando R2 es morfolino no sustituido, RN3 y RN4 junto con el átomo de N al cual están unidos forman un morfolino no sustituido y R7 es fenilo no sustituido, y X5 es CH, entonces X6 no es N y X8 no es CH, o X6 no es CH y X8 no es N, y cuando R2 es piperidinilo no sustituido, RN3 y RN4 junto con el átomo de N al cual están unidos forman un piperidinilo no sustituido y R7 es fenilo no sustituido, y X5 es CH, entonces X6 no es CH y X8 no es N.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73890205P | 2005-11-22 | 2005-11-22 | |
| GB0524047A GB0524047D0 (en) | 2005-11-25 | 2005-11-25 | Compounds |
| US82330906P | 2006-08-23 | 2006-08-23 | |
| US82330806P | 2006-08-23 | 2006-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057626A1 true AR057626A1 (es) | 2007-12-05 |
Family
ID=37533284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105124A AR057626A1 (es) | 2005-11-22 | 2006-11-22 | Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080194546A1 (es) |
| EP (1) | EP1954699B1 (es) |
| JP (1) | JP5161102B2 (es) |
| KR (1) | KR101464384B1 (es) |
| AR (1) | AR057626A1 (es) |
| AU (1) | AU2006318948B2 (es) |
| CA (1) | CA2628920C (es) |
| EC (1) | ECSP088536A (es) |
| HR (1) | HRP20120963T1 (es) |
| IL (1) | IL191196A (es) |
| NO (1) | NO341055B1 (es) |
| PL (1) | PL1954699T3 (es) |
| TW (1) | TWI452047B (es) |
| UY (1) | UY29938A1 (es) |
| WO (1) | WO2007060404A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
| CA2633757A1 (en) * | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
| MY148688A (en) | 2006-08-23 | 2013-05-31 | Kudos Pharm Ltd | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| UA96304C2 (en) * | 2006-08-23 | 2011-10-25 | Кудос Фармасьютикалз Лимитед | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| US20100204222A1 (en) * | 2007-09-17 | 2010-08-12 | GlaxoSmithKline, LLC | Pyridopyrimidine derivatives as p13 kinase inhibitors |
| MX2010004074A (es) * | 2007-10-15 | 2010-07-02 | Astrazeneca Ab | Combinacion 059. |
| US8466151B2 (en) | 2007-12-26 | 2013-06-18 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| BRPI0908100A2 (pt) * | 2008-02-21 | 2015-10-06 | Astrazeneca Ab | produto combinação, uso de um composto, e, método de tratar câncer |
| ES2398423T3 (es) * | 2008-06-20 | 2013-03-19 | Astrazeneca Ab | Composiciones con y procedimiento para pirido[2,3-D]pirimidinas sustituídas con metilmorfolina |
| EP2318406B1 (en) | 2008-07-17 | 2016-01-27 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| AU2009276339B2 (en) * | 2008-07-31 | 2012-06-07 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
| EP2349275B1 (en) * | 2008-10-31 | 2017-03-08 | Novartis AG | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor. |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| JP2013511526A (ja) | 2009-11-18 | 2013-04-04 | ノバルティス アーゲー | 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物 |
| WO2011067356A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Polymorphs of a mek inhibitor |
| WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
| JP6114554B2 (ja) | 2010-02-03 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定 |
| EP2539337A1 (en) * | 2010-02-22 | 2013-01-02 | F. Hoffmann-La Roche AG | Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use |
| US8748428B2 (en) | 2010-03-30 | 2014-06-10 | Novartis Ag | Use of a PKC inhibitor |
| US8987272B2 (en) | 2010-04-01 | 2015-03-24 | Critical Outcome Technologies Inc. | Compounds and method for treatment of HIV |
| ES2689177T3 (es) | 2010-04-13 | 2018-11-08 | Novartis Ag | Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer |
| CA2803055A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Heteroaryl compounds and compositions as protein kinase inhibitors |
| WO2012099581A1 (en) | 2011-01-19 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Dihydrofuropyrimidine compounds |
| CA2843887A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
| CN102911172A (zh) * | 2011-08-04 | 2013-02-06 | 上海恒瑞医药有限公司 | 杂芳基并嘧啶类衍生物、其制备方法和用途 |
| CN103374021B (zh) * | 2012-04-21 | 2015-10-28 | 通化济达医药有限公司 | 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| WO2014085528A1 (en) | 2012-11-29 | 2014-06-05 | Merck Patent Gmbh | Azaquinazoline carboxamide derivatives |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| TWI631949B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| SG10201708111YA (en) | 2013-04-17 | 2017-11-29 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| CA2909629C (en) | 2013-04-17 | 2022-12-13 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| MX377267B (es) | 2013-04-17 | 2025-03-07 | Signal Pharm Llc | Tratamiento de cáncer con dihidropirazino-pirazinas. |
| CA3143529A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| CN106008559B (zh) * | 2015-03-25 | 2020-10-16 | 中国科学院上海药物研究所 | 取代吡啶并嘧啶类化合物的合成工艺 |
| WO2018144791A1 (en) * | 2017-02-03 | 2018-08-09 | Millennium Pharmaceuticals, Inc. | Combination of vps34 inhibitors and mtor inhibitors |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
| WO2019085996A1 (zh) * | 2017-11-06 | 2019-05-09 | 南京明德新药研发股份有限公司 | 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物 |
| WO2021133509A1 (en) * | 2019-12-27 | 2021-07-01 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as mtor inhibitors |
| IL294504A (en) | 2020-01-13 | 2022-09-01 | Verge Analytics Inc | Converted pyrazolo-pyrimidines and their uses |
| WO2021247859A1 (en) * | 2020-06-03 | 2021-12-09 | Yumanity Therapeutics, Inc. | Pyridopyrimidines and methods of their use |
| JP2023540228A (ja) * | 2020-08-26 | 2023-09-22 | インベンティスバイオ カンパニー リミテッド | ヘテロアリール基化合物、その製造方法および使用 |
| WO2024057013A1 (en) * | 2022-09-12 | 2024-03-21 | Exscientia Ai Limited | Nlrp3 modulators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2940972A (en) * | 1957-06-27 | 1960-06-14 | Thomae Gmbh Dr K | Tri-and tetra-substituted pteridine derivatives |
| US4560685A (en) * | 1984-06-18 | 1985-12-24 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics |
| DE3445298A1 (de) * | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
| US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
| PT1481970E (pt) * | 1999-09-07 | 2006-07-31 | Syngenta Participations Ag | Novos herbicidas |
| KR100774855B1 (ko) * | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| GB0428475D0 (en) * | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
-
2006
- 2006-11-20 WO PCT/GB2006/004327 patent/WO2007060404A1/en not_active Ceased
- 2006-11-20 JP JP2008541809A patent/JP5161102B2/ja active Active
- 2006-11-20 KR KR1020087015084A patent/KR101464384B1/ko not_active Expired - Fee Related
- 2006-11-20 EP EP06808609A patent/EP1954699B1/en active Active
- 2006-11-20 HR HRP20120963TT patent/HRP20120963T1/hr unknown
- 2006-11-20 PL PL06808609T patent/PL1954699T3/pl unknown
- 2006-11-20 AU AU2006318948A patent/AU2006318948B2/en not_active Ceased
- 2006-11-20 CA CA2628920A patent/CA2628920C/en active Active
- 2006-11-21 UY UY29938A patent/UY29938A1/es not_active Application Discontinuation
- 2006-11-22 AR ARP060105124A patent/AR057626A1/es not_active Application Discontinuation
- 2006-11-22 TW TW095143285A patent/TWI452047B/zh not_active IP Right Cessation
-
2007
- 2007-08-21 US US11/842,927 patent/US20080194546A1/en not_active Abandoned
-
2008
- 2008-05-01 IL IL191196A patent/IL191196A/en active IP Right Grant
- 2008-05-06 NO NO20082101A patent/NO341055B1/no not_active IP Right Cessation
- 2008-06-16 EC EC2008008536A patent/ECSP088536A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080070079A (ko) | 2008-07-29 |
| AU2006318948A1 (en) | 2007-05-31 |
| WO2007060404A1 (en) | 2007-05-31 |
| NO20082101L (no) | 2008-08-15 |
| CA2628920C (en) | 2015-12-29 |
| PL1954699T3 (pl) | 2013-01-31 |
| TWI452047B (zh) | 2014-09-11 |
| KR101464384B1 (ko) | 2014-11-21 |
| JP5161102B2 (ja) | 2013-03-13 |
| CA2628920A1 (en) | 2007-05-31 |
| TW200738706A (en) | 2007-10-16 |
| AU2006318948B2 (en) | 2011-02-24 |
| UY29938A1 (es) | 2007-06-29 |
| HK1124039A1 (en) | 2009-07-03 |
| EP1954699A1 (en) | 2008-08-13 |
| EP1954699B1 (en) | 2012-09-19 |
| ECSP088536A (es) | 2008-07-30 |
| JP2009516727A (ja) | 2009-04-23 |
| HRP20120963T1 (hr) | 2012-12-31 |
| US20080194546A1 (en) | 2008-08-14 |
| NO341055B1 (no) | 2017-08-14 |
| IL191196A (en) | 2016-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057626A1 (es) | Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor | |
| CO6150164A2 (es) | Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor | |
| ES2662397T3 (es) | Inhibidores de la quinasa reguladora de la señal de apoptosis | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR054081A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas | |
| AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
| AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
| CO6251251A2 (es) | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares | |
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR069804A1 (es) | Agonistas del receptor glucocorticoide c20- c21 sustituido | |
| AR073574A1 (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad | |
| AR074790A1 (es) | Derivados de isooxazol sustituidos, composiciones farmaceuticas y para el control de parasitos que los comprenden y su uso en metodos para controlar parasitos en y sobre animales de sangre caliente. | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| AR066020A1 (es) | Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1. | |
| CO6260132A2 (es) | Derivados de oxadiazol como inhibidores de dgat | |
| CO6410301A2 (es) | 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |